In response to the "IPO data fraud" incident, Huada Gene confirmed that it received a letter from the Shenzhen Stock Exchange.
Recently, some media have revealed that in the IPO declaration of Huada Gene in 2015 and 2017, the source of income from its main business, the reproductive health service, was inconsistent in the production and sales data in 2014; the controlling shareholder of the company involved litigation, but Not disclosed in the IPO filing materials. In response to the "IPO data fraud" incident, Huada Gene announced today that it has received a letter of inquiry from the Shenzhen Stock Exchange. It is reported that the Shenzhen Stock Exchange’s inquiry letter expressed concern about the matter. At the same time, the Shenzhen Stock Exchange also asked the BGI to verify the above two things and added the following questions: 1. In the two versions of the IPO declaration submitted by your company on December 11, 2015 and March 14, 2017, the reason for the inconsistent production and sales of reproductive health services in 2014. 2. The controlling shareholder of the company is involved in litigation cases related to the construction project of Huada Gene Center and the “Shenzhen Construction Land Planning Permit†of BH-2011-0032. Please inform the company whether the current progress of the above-mentioned cases and the impact on the company are undisclosed. Please ask your company to give a written explanation on the above issues, and submit the relevant materials to our department on November 28. Founded in 1999, Huada Gene is the world's largest genomics research and development organization. Its main business is to provide genomics diagnosis and research services for medical institutions, scientific research institutions, enterprises and institutions through genetic testing and other means. In July of this year, the successful listing of Huada Gene brought the concept of “ gene sequencing †to a climax. Previously, Huada Gene was still a new star in the A-share market, and the incident that was exposed this time can be said to be a big blow. As of now, the market value of Huada Gene has shrunk to 76.343 billion yuan, and in addition to indicating that it has received an inquiry letter, it has not made any positive response.
Upper limb locking plate system consists of ulna radius locking plates,humerus locking plates,clavicle locking plates,scapula locking plates,locking screw and cortical screw.
The locking plate also has locking or non-locking screw holes for different trauma screws.In the internal fixation of the upper limb, four locking screws are generally used, which are mainly divided into 2.7mm and 3.5mm diameter.
olecranon plate,humerus fracture,volar distal radius plate,clavicle fracture Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.aomedortho.com